Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-10-07
2004-11-23
Spivack, Phyllis (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06821995
ABSTRACT:
FIELD OF THE INVENTION
The present invention concerns methods of treating subjects afflicted with Batten disease.
BACKGROUND OF THE INVENTION
Batten disease is a group of neurodegenerative disorders characterized by cognitive decline, spasticity and seizures due to neuronal cell loss, and blindness due to retinitis pigmentosa. The juvenile form of Batten disease is an autosomal recessive neurodegenerative disease of childhood (R.-M. Boustany, et al.,
Am. J. Med. Genet. Suppl
. 5: 47-58 (1988)). It is clinically characterized by onset at age 5-6 years with progressive blindness, generalized and myoclonic seizures, cognitive and motor decline and death in the mid to late twenties (R.-M. Boustany and E. H. Kolodny,
Rev. Neurol
. (Paris) 145: 105-110 (1989); R.-M. Boustany,
Am. J. Med. Genet
. 42: 533-535 (1992); R.-M. Boustany and P. Filipek,
J. Inher. Metab. Dis
. 16: 252-255 (1993)). No suitable treatments for Batten disease are currently available. Therefore, there is an urgent need for the development of new ways to treat Batten disease.
SUMMARY OF THE INVENTION
A first aspect of the present invention is a method of treating Batten disease in a subject in need thereof. The method comprises administering to said subject an active agent selected from the group consisting of flupirtine and the pharmaceutically acceptable salts thereof in an amount effective to treat Batten disease in that subject. The administering step is preferably an oral administering step, and the active agent is preferably flupirtine maleate.
A second aspect of the present invention is the use of flupirtine or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Batten disease.
Flupirtine (available in some regions in the flupirtine maleate form as the drug Katodolon® from ASTAmedica) was developed as a centrally acting, non-opiate analgesic. It is currently in use in Germany, Brazil, Italy and other countries. It has been used in adults and children safety and chronically for over 12 months without undue side effect or addiction. It has been shown to counteract apoptosis in retinal pigment epithelial cells and neuronal cells in culture. It has been shown to reduce the area of ischemia induced by stroke in rats pretreated with it. It has been shown to have anticonvulsant effects and very powerful muscle relaxant effects as well. The use of flupirtine in the treatment of Batten disease has neither been suggested nor disclosed.
The present invention is explained in greater detail in the specification set forth below.
REFERENCES:
patent: 4481205 (1984-11-01), von Bebenburg et al.
patent: 4673666 (1987-06-01), Hettche et al.
patent: 4834965 (1989-05-01), Martani et al.
patent: 5162346 (1992-11-01), Lobisch et al.
patent: 5284861 (1994-02-01), Lobisch et al.
patent: 5503845 (1996-04-01), Goede et al.
patent: 5721258 (1998-02-01), Schwarz et al.
patent: 5959115 (1999-09-01), Olbrich et al.
patent: 6034111 (2000-03-01), Pergande et al.
patent: 6124326 (2000-09-01), Pergande et al.
patent: 6194000 (2001-02-01), Smith et al.
patent: 6610324 (2003-08-01), Stoll
patent: WO 95/05175 (1995-02-01), None
patent: WO 97/49398 (1997-12-01), None
Perovic, Sanja, et al.,Flupirtine increases the levels of glutathione and Bcl-2 in hNT(human Ntera/D1)neurons: mode of action of the drug-mediated anti-apoptotic effect, European Journal of Pharmacology, vol. 317, pp. 157-164 (1996).
Puranam, K., et al.,Upregulation of Bcl-2 and Elevation of Ceramide in Batten Disease, Neuropediatrics, vol. 28, pp. 37-41 (1997).
Riethmüller-Winzen, H.,Flupirtine in the treatment of post-operative pain, Postgraduate Medical Journal, vol. 63, pp. 61-66 (1987).
Schwarz, M., et al.,Antiparkinsonian effect of flupirtine in monoamine-depleted rats, Journal of Neural Transmission, vol. 103, pp. 581-590 (1996).
Müller, Werner E.G., et al.,Protection of Flupirtine of &bgr;-Amyloid-Indiced Apoptosis in Neuronal Cells in Vitro: Prevention of Amyloid-Indiced Glutathione Depletion, Journal of Neurochemistry, vol. 68, pp. 2371-2377 (1997).
Perovic, Sanja, et al.,Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and Prion diseases, Mechanisms of Ageing and Development, vol. 101, pp. 1-19 (1998).
Lane, Steven C., et al.,Apoptosis as the Mechanism of Neurodegeneration in Batten's Disease, vol. 67, pp. 677-683 (1996).
Puranam, Kasturi L., et al.,CLN3 Defines a Novel Antiapoptotic Pathway Operative in Neurodegeneration and Mediated by Ceramide, Molecular Genetics and Metabolism, vol. 66, pp. 294-308 (1999).
Duke University
Myers Bigel & Sibley & Sajovec
Spivack Phyllis
LandOfFree
Method of treating batten disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating batten disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating batten disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3332586